Oculis Holding AG

NASDAQ:OCS

Biotechnology

Healthcare
$7.39 -2.43%

-$0.28 today

Market cap
$456.20M
Beta
0.13
P/E (TTM)
-5.5
EPS (TTM)
-$1.61
52W Low $10.52High $34.48

Volume 0.31M

Average 0.65M

OCS Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Oculis Holding AGNASDAQ: OCS

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -CHF 17.87M, compared with CHF 32.17M a year earlier. Trailing-twelve-month net change in cash was CHF 3.82M.

Context

  • Net change in cash increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -CHF 17.87M or moves back toward the trailing-twelve-month quarterly average of CHF 955.71K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-CHF 17.87M-150.9% QoQ
Last fiscal yearDec 2025
CHF 57.17M+638.4% YoY
LTMMar 2026
CHF 3.82M-89.2% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-155.6%——
1 year+638.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

CHF · from the cash flow

Latest · FY2025
57.17M CHF
Year-over-year change
+638.4%
4-year CAGR
+8.5%

Net Change in Cash vs competitors

How OCS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -89.2% is the 4th highest of 6, against a peer median of +122.8%.
  • Net change in cash amounts to 758.5% of revenue for OCS, versus a peer median of 353.5%.
OCS Competitors
Net Change in Cash for OCS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OCULOcular Therapeutix, Inc.LTM Mar 2026$317.02M USD+337.7%—609.2%
HROWHarrow Health, Inc.LTM Mar 2026$27.92M USD+1640.7%-22.0%10.4%
EYPTEyePoint Pharmaceuticals, Inc.LTM Mar 2026$7.45M USD-96.0%—97.8%
OCSOculis Holding AGLTM Mar 2026CHF 3.82M CHF-89.2%—758.5%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$2.82M USD-92.9%—847.0%
OKYOOKYO Pharma LimitedFY2025$734.05K USD+122.8%——
Peer median (excluding OCS) —+122.8%-22.0%353.5%

Competitors are the stored peer set for OCS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

CHF
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(18.52M)(38.64M)(88.7M)(85.94M)(94.51M)
Depreciation & Amortization235K299K287K406K546K
Deferred Income Tax00000
Stock-Based Compensation328K804K3.61M9.78M16.04M
Change in Working Capital(791K)6M(12.99M)14.16M(70.67K)
Accounts Receivables233K(152K)36K247K1.9M
Inventory00000
Accounts Payables30K3.04M3.73M(1.71M)(1.86M)
Other Working Capital(1.05M)3.11M(16.76M)15.62M(106.97K)
Other Non-Cash Items4.93M6.47M43.95M14.09M15.77M
Operating Cash Flow(13.83M)(25.07M)(53.85M)(47.5M)(62.22M)
Capital Expenditures(28K)(3.55M)(48K)(230K)(287.47K)
Acquisitions (Net)00000
Purchases of Investments00(54.16M)(17.33M)(58.05M)
Sales of Investments00000
Other Investing Activities0(3.48M)000
Investing Cash Flow(28K)(3.55M)(54.21M)(17.56M)(59.38M)
Debt Repayment(98K)(159K)(158K)(274K)(373K)
Common Stock Issued00135.62M53.54M178.95M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(804K)(157K)(5.79M)763K16.77K
Financing Cash Flow55.19M1.71M129.67M54.03M178.6M
Effect of Forex Changes(16K)418K(3.08M)407K174.39K
Net Change in Cash41.33M(26.49M)18.54M(10.62M)57.17M
Free Cash Flow(13.85M)(28.62M)(53.89M)(47.73M)(62.51M)

Oculis Holding AG

NASDAQ:OCS

Intrinsic Alpha fair value

Locked

Current Price

$7.39

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.